Press release
Anti-inflammatory Drugs Market Size to Reach US$ 198.92 Billion by 2031, Growing at 8.7% CAGR
Anti-Inflammatory Drugs Market
Anti-inflammatory drugs reduce inflammation by targeting mediators including prostaglandins, cytokines, and leukotrienes. As global populations age and chronic disease burdens rise, these drugs remain a cornerstone of treatment. According to the CDC (June 2024), arthritis alone is projected to affect around 78 million adults in the U.S. by 2040, representing a major catalyst for demand.
Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/anti-inflammatory-drugs-market?utm_source=OpenPR&utm_campaign=Onkar
Market Drivers and Restraints
Rising Prevalence of Inflammatory Disorders Boosts Demand
The growing incidence of chronic inflammatory and autoimmune conditions is a key market driver. Rheumatoid arthritis, IBD, and psoriasis are increasingly widespread globally, especially among aging populations. In April 2024, an NCBI report estimated that rheumatoid arthritis affects roughly 1.3 million adults in the U.S., with IBD incidence rising by 5.2% annually among senior populations.
Pharmaceutical innovation and new drug formulations also play pivotal roles. For instance, a 2023 initiative by India's Ministry of Science & Technology introduced a system combining anti-inflammatory agents with advanced delivery methods for improved therapeutic targeting. Likewise, breakthroughs in biologics and biosimilars that act on specific inflammatory pathways are enhancing efficacy and safety profiles, extending market growth opportunities.
Side Effects Impeding Broader Adoption
Despite their effectiveness, many anti-inflammatory drugs-particularly NSAIDs and corticosteroids-carry adverse effects that can limit usage. According to a 2023 NCBI article, NSAIDs may cause gastrointestinal, renal, cardiovascular, hepatic, and hematologic complications, in addition to allergic and respiratory reactions. These challenges underscore the growing importance of precision therapies, biologics, and safer delivery systems to maintain adherence and minimize risks.
Get Customization in the Report as Per Your Business Requirements: https://www.datamintelligence.com/customize/anti-inflammatory-drugs-market?utm_source=OpenPR&utm_campaign=Onkar
Market Segmentation
By Drug Class
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) remain the dominant drug class segment, long relied upon for pain and inflammation management across multiple conditions. They act by inhibiting cyclooxygenase (COX) enzymes responsible for prostaglandin synthesis. Widely used NSAIDs include ibuprofen, naproxen, and diclofenac.
Recent approvals further reinforce segment expansion. In July 2024, ANI Pharmaceuticals gained FDA approval for a delayed-release naproxen formulation to treat arthritis and inflammatory pain. Similarly, Strides Pharma received approval for 220 mg naproxen sodium soft gel capsules in 2022, offering affordable, over-the-counter options.
Biologics Segment Experiencing Fastest Growth
Biologics represent the fastest-growing drug class, revolutionizing inflammatory disease treatment through targeted action on molecules such as cytokines. Unlike conventional anti-inflammatories, biologics deliver precision therapy with reduced off-target effects. Rising incidences of autoimmune conditions such as rheumatoid arthritis and IBD are amplifying demand for biologics and biosimilars.
By Application
Arthritis Segment Holds Largest Share
Arthritis remains the largest application segment in the anti-inflammatory drugs market. Joint inflammation, stiffness, and chronic pain continue to affect a significant portion of the global population. As per CDC data (March 2024), arthritis impacts about 54 million Americans-one in four adults-making it a top driver of drug demand.
Therapeutic innovations, including biologics and disease-modifying antirheumatic drugs (DMARDs), have improved management and patient outcomes, accelerating adoption. The increasing prevalence of osteoarthritis and rheumatoid arthritis, linked to aging and obesity trends, further boosts ongoing market expansion.
COPD Segment Exhibiting Fastest Growth
COPD is the fastest-growing application segment. The World Health Organization (November 2024) reported COPD as the fourth leading global cause of death, responsible for 3.5 million deaths in 2021. Bronchodilators, corticosteroids, and PDE4 inhibitors remain central to treatment, while combination therapies are delivering improved outcomes.
Regional variations in risk factors-tobacco use in developed nations and indoor pollution in low- and middle-income countries-underscore the global scale of demand for anti-inflammatory therapies in respiratory diseases.
Purchase This Exclusive Report at Just USD 4363 Only: https://www.datamintelligence.com/buy-now-page?report=anti-inflammatory-drugs-market?utm_source=OpenPR&utm_campaign=Onkar
Regional Insights
North America: Market Leader with Strong Research Backbone
North America dominates the global market, supported by widespread chronic disease prevalence, robust healthcare systems, and the presence of leading pharmaceutical companies. Rising cases of arthritis, psoriasis, and IBD continue to bolster demand for advanced anti-inflammatory therapies.
Collaborative research and FDA drug approvals enhance the region's market strength. In April 2024, Glenmark Pharmaceuticals secured FDA approval for acetaminophen-ibuprofen combination tablets (250 mg/125 mg). Similarly, collaborative research between the Hudson Institute of Medical Research and Adiso Therapeutics is advancing inflammasome-targeted drug development.
Asia Pacific: Fastest-Growing Region
Asia Pacific is anticipated to register the fastest market growth through 2031. The region's expanding elderly population, higher rates of COPD and IBD, and increasing awareness of chronic inflammatory diseases support strong demand. Governments and pharmaceutical companies are also advancing R&D and improving accessibility to innovative biologic drugs.
Key contributors such as China, Japan, and India are improving healthcare infrastructure and accelerating approvals for novel anti-inflammatory treatments.
Competitive Landscape
Major market players driving innovation include:
AbbVie Inc.
Johnson & Johnson Services, Inc.
Pfizer Inc.
F. Hoffmann-La Roche Ltd
AstraZeneca
Novartis AG
Amgen Inc.
GSK plc
Merck & Co., Inc.
Bristol-Myers Squibb Company
Viatris Inc.
Emerging players such as UCB S.A., Rapport Therapeutics, and Apogee Therapeutics, Inc. are strengthening market competitiveness through next-generation biologics and advanced delivery mechanisms.
Key Developments
July 2024: Hikma Pharmaceuticals PLC received a permanent HCPCS J-code from CMS for COMBOGESIC IV, a combination analgesic of acetaminophen and ibuprofen for adult pain management.
July 2024: Alembic Pharmaceuticals obtained FDA approval for Bremen Ophthalmic Solution (0.07%), an NSAID indicated for post-cataract inflammation and ocular pain.
March 2024: Endo International plc launched Ibuprofen-Famotidine 800 mg/26.6 mg tablets, providing effective pain relief while reducing gastrointestinal risks associated with traditional NSAIDs.
Contact Us
Mr. Sai Kiran
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Visit Our Website: https://www.datamintelligence.com
About Us
DataM Intelligence 4Market Research is a comprehensive market intelligence platform offering syndicated and customized reports along with expert consulting across multiple industries, including chemicals, healthcare, agriculture, food & beverages, and more. With extensive experience and a strategy-focused approach, DataM provides businesses and individuals with reliable market insights, statistical forecasts, and personalized research solutions to help them make informed decisions and successfully bring innovations to market.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anti-inflammatory Drugs Market Size to Reach US$ 198.92 Billion by 2031, Growing at 8.7% CAGR here
News-ID: 4210056 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
Precision Farming Market Driven by AI, VRA, and Sustainability Adoption in Key R …
The global precision farming market is undergoing rapid transformation, powered by advanced technologies such as Artificial Intelligence (AI) and Generative AI (GenAI). These tools modernize conventional farming by automating crop monitoring, yield forecasting, and resource allocation, reducing human error and operational time. Predictive analytics and real-time monitoring help farmers make data-driven decisions to optimize land use, inputs, and productivity, benefiting both agricultural and environmental objectives. Integration of GenAI enables actionable…
Green Steel Market to Expand at 126.7% CAGR by 2031, Driven by Decarbonization a …
Global Green Steel Market reached US$ 201.3 million in 2022 and is expected to reach US$ 140,435.7 million by 2031, growing with a CAGR of 126.7% during the forecast period 2024-2031. The rapid expansion reflects a fundamental transformation within the steel industry, which is shifting toward low-carbon production methods powered by renewable energy such as solar, wind, and hydropower.
Green steel-produced using sustainable and emission-reducing energy sources-represents a key step toward…
Energy as a Service Market to Grow at 13.5% CAGR by 2031 Driven by Renewable Dem …
The global Energy as a Service (EaaS) market is set to witness remarkable expansion, projected to grow at a compound annual growth rate (CAGR) of 13.5% between 2024 and 2031. The market's upward trajectory is driven by rising demand for sustainable, cost-efficient energy solutions and increasing integration of renewable energy sources across industrial and commercial applications.
EaaS operates on a model where consumers leverage managed energy solutions without owning or maintaining…
United States Chronic Spontaneous Urticaria (CSU) Treatment Market 2025-2033: Ri …
The Global Chronic Spontaneous Urticaria (SCU) Treatment Market reached US$ 719.94 Million in 2023, with a rise of US$ 778.40 Million in 2024 and is expected to reach US1,654.42 Million by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033.
This Chronic Spontaneous Urticaria (SCU) Treatment market addresses therapies for chronic hives without identifiable triggers. Rising incidence of autoimmune-related urticaria drives demand for effective treatments. Biologic drugs targeting…
More Releases for IBD
Ace Therapeutics Unveils Imaging Services for Precise Characterization of IBD An …
Ace Therapeutics launched its translational imaging services specifically designed to accurately characterize Inflammatory Bowel Disease (IBD) animal models.
New York, USA - May 28, 2025 - Ace Therapeutics, a leader in preclinical research solutions, launched its translational imaging solutions specifically designed to accurately characterize Inflammatory Bowel Disease (IBD) animal models. This breakthrough offering empowers researchers with high-resolution, quantitative data to enhance drug development and mechanistic studies.
Image: https://www.getnews.info/uploads/3c0755ac659fa5075e809ffd1b893496.jpg
Imaging techniques play a crucial…
Inflammatory Bowel Disease (IBD) Market Size, Growth Insights, and Future Trends
Inflammatory Bowel Disease (IBD) continues to pose significant challenges for individuals and healthcare systems worldwide. With its increasing prevalence, the demand for effective treatments is driving market growth. The IBD treatment market is projected to grow from USD 19.91 billion in 2023 to USD 33.19 billion by 2032, reflecting a compound annual growth rate (CAGR) of 5.5% during the forecast period.
Download Statistical Data: https://www.towardshealthcare.com/download-statistics/5149
Key Market Highlights
• Crohn's Disease Dominates: Crohn's disease…
Canada Inflammatory Bowel Disease (IBD) Market Size & Growth Analysis Report, 20 …
The Canada IBD market is estimated to grow significantly at a CAGR of around 5.2% during the forecast period. Rising prevalence and incidence of IBD across the country is the major driving factor for the market. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per CCC, in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn’s disease,…
Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031
Visiongain has published a new report on Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031: Forecasts by Drug Class (Biologics, Aminosalicylates, Corticosteroids, Antibiotics, Immunomodulators, Others), by Indication (Crohn’s Disease, Ulcerative Colitis), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading IBD Drug Companies AND COVID-19 Recovery Scenarios.
Global Inflammatory Bowel Disease (IBD) drugs market was valued at US$ US$xx…
US Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Forecast 20 …
The US IBD therapeutics market is estimated to grow significantly at a CAGR of around 4.7% during the forecast period. The factors such as the significant prevalence of IBD such as Crohn’s disease and ulcerative colitis across the country contributing to the market growth. As per the Centers for Disease Control and Prevention (CDC), the prevalence of Crohn’s disease and ulcerative colitis in the US was 201 and 238 per…
Global Inflammatory Bowel Disease (IBD) Therapeutics Market, Share, Trends & For …
The global IBD therapeutics market is estimated to grow significantly at a CAGR of around 5.0% during the forecast period. The rise in the number of IBD such as Crohn's disease and ulcerative colitis is augmenting the growth of the global IBD therapeutics market. The increasing prevalence of IBD results in the need for research for the treatment of IBD and innovations in healthcare systems to manage this complex and…
